Chemical manufacturer resumes raw material production to increase production of Avigan April 17 at 17:25
To increase production of Avigan, which is undergoing clinical trials to receive national approval as a new coronavirus treatment, Japanese chemical manufacturers have resumed production of organic compounds used as raw materials for Avigan, and a pharmaceutical company It was announced to supply to.
Avigan is a new influenza drug developed by Fujifilm Toyama Chemical and is currently undergoing clinical trials to receive national approval as a new coronavirus treatment.
Denka, a chemical manufacturer headquartered in Tokyo, will produce the organic compound "diethyl malonate" as a raw material for the Avigan from next month and announce that it will be supplied to Fujifilm Toyama Chemical.
Denka is the only manufacturer in Japan that manufactures diethyl malonate, but had suspended production facilities in April 2017.
According to the company, in response to a request from the country to use domestic raw materials to create a consistent domestic supply system for Avigan, the company decided to restart its facilities and resume production.
Denka commented, "We regard measures against the new coronavirus as a social responsibility, and we will quickly build a production system and ensure reliable supply."